Champions Historical Income Statement
| CSBR Stock | USD 4.31 0.02 0.46% |
Historical analysis of Champions Oncology income statement accounts such as Interest Expense of 38.3 K, Selling General Administrative of 11.6 M or Total Revenue of 52.7 M can show how well Champions Oncology performed in making a profits. Evaluating Champions Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Champions Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Champions Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Champions Oncology is a good buy for the upcoming year.
Champions |
About Champions Income Statement Analysis
Champions Oncology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Champions Oncology shareholders. The income statement also shows Champions investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Champions Oncology Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Champions Oncology generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Champions Oncology. It is also known as Champions Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Champions Oncology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Champions Oncology is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most accounts from Champions Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Champions Oncology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.At this time, Champions Oncology's Total Operating Expenses is relatively stable compared to the past year. As of 11/29/2024, Total Other Income Expense Net is likely to grow to about 50.4 K, though EBIT is likely to grow to (6.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 25.5M | 24.3M | 20.8M | 21.8M | Total Revenue | 49.1M | 53.9M | 50.2M | 52.7M |
Champions Oncology income statement Correlations
Click cells to compare fundamentals
Champions Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Champions Oncology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.2M | 1.6M | 2.4M | 3.2M | 1.9M | 2.0M | |
| Interest Expense | 39K | 712K | 71K | 24K | 27.6K | 38.3K | |
| Selling General Administrative | 6.6M | 6.5M | 9.1M | 10.2M | 11.1M | 11.6M | |
| Total Revenue | 32.1M | 41.0M | 49.1M | 53.9M | 50.2M | 52.7M | |
| Gross Profit | 15.2M | 19.6M | 25.5M | 24.3M | 20.8M | 21.8M | |
| Other Operating Expenses | 33.6M | 40.7M | 48.5M | 58.3M | 57.5M | 60.4M | |
| Operating Income | (1.5M) | 338K | 607K | (4.4M) | (7.4M) | (7.0M) | |
| Ebit | (1.5M) | (1.2M) | (179K) | (5.3M) | (6.9M) | (6.6M) | |
| Ebitda | (308K) | 366K | 2.2M | (2.1M) | (5.1M) | (4.8M) | |
| Cost Of Revenue | 16.9M | 21.5M | 23.6M | 29.5M | 29.4M | 30.9M | |
| Total Operating Expenses | 16.7M | 19.2M | 24.9M | 28.8M | 28.1M | 29.5M | |
| Income Before Tax | (1.8M) | 409K | 583K | (5.3M) | (7.3M) | (6.9M) | |
| Net Income | (2.0M) | 362K | 548K | (5.3M) | (7.3M) | (6.9M) | |
| Income Tax Expense | 130K | 75K | 35K | 68K | (32K) | (30.4K) | |
| Total Other Income Expense Net | (377K) | 71K | (24K) | (11K) | 48K | 50.4K | |
| Net Income Applicable To Common Shares | (2.0M) | 362K | 548K | (5.3M) | (6.1M) | (6.4M) | |
| Selling And Marketing Expenses | 4.2M | 5.5M | 6.4M | 7.0M | 7.1M | 4.3M | |
| Research Development | 5.9M | 7.2M | 9.4M | 11.5M | 9.5M | 5.2M | |
| Net Income From Continuing Ops | (2.0M) | 334K | 548K | (5.3M) | (7.3M) | (7.6M) | |
| Non Operating Income Net Other | (42K) | 71K | (24K) | (11K) | (12.7K) | (13.3K) | |
| Tax Provision | 130K | 75K | 35K | 68K | (32K) | (30.4K) | |
| Reconciled Depreciation | 825K | 1.2M | 1.6M | 2.2M | 1.9M | 1.2M |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
| 0.49 | VERV | Verve Therapeutics | PairCorr |
| 0.46 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.36 | EQ | Equillium | PairCorr |
| 0.35 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.